A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
- Conditions
- Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT03499899
- Locations
- πΊπΈ
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
πΉπNovartis Investigative Site, Songkla, Thailand
πΊπΈHighlands Oncology Group, Fayetteville, Arkansas, United States
Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
- Conditions
- Inflammatory Acne
- Interventions
- Drug: LYS006 2 mgDrug: PlaceboDrug: LYS006 20 mg
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT03497897
- Locations
- π³π±
Novartis Investigative Site, Nijmegen, Netherlands
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT03491215
- Locations
- πͺπΈ
Novartis Investigative Site, Madrid, Spain
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 196
- Registration Number
- NCT03484923
- Locations
- πΊπΈ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
πΊπΈUniversity of California Los Angeles, Los Angeles, California, United States
πΊπΈMassachusetts General Hospital Massachusetts Gen. Hospital CC, Boston, Massachusetts, United States
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 360
- Registration Number
- NCT03481660
- Locations
- πΉπ·
Novartis Investigative Site, Kocaeli, Turkey
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 566
- Registration Number
- NCT03481634
- Locations
- π¬π§
Novartis Investigative Site, Nottingham, United Kingdom
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT03474965
- Locations
- πΊπΈ
University Of Alabama, Birmingham, Alabama, United States
πΊπΈUniv of Florida College of Medicine, Gainesville, Florida, United States
πΊπΈJoe DiMaggio Childrens Hospital, Hollywood, Florida, United States
Safety Study of LLF580 in Obese Volunteers
- Conditions
- Obesity
- Interventions
- Biological: LLF580Drug: Placebo
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT03466203
- Locations
- πΊπΈ
Novartis Investigative Site, Knoxville, Tennessee, United States
Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients
- Conditions
- BK Virus Nephropathy
- Interventions
- Biological: MAU868Biological: Placebo
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03456999
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1382
- Registration Number
- NCT03447769
- Locations
- πΊπΈ
Cancer Center of Kansas Dept.ofCancerCtr.ofKansas, Wichita, Kansas, United States
πΊπΈFlorida Cancer Specialists, West Palm Beach, Florida, United States
πΊπΈAdvanced Medical Specialties Drug Ship - 2, Miami, Florida, United States